Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

67146 Press Releases
DateTitleCompany
11 Jun 12 Sanofi Submits Application for Regulatory Approval for Lyxumia® (lixisenatide) for the Treatment of Type 2 Diabetes in Japan Sanofi
11 Jun 12 Novartis drug Gilenya® shows long-term efficacy and safety according to new data from extension of phase III head-to-head study Novartis
11 Jun 12 Cara Therapeutics Reports Positive Results from Phase II Trial of Novel Peripheral Kappa Agonist, CR845, in Acute Post-Operative Pain CARA THERAPEUTICS,
Published by
PR Newswire
11 Jun 12 Crain's FastFifty Ranks Rising Medical Solutions Fastest Growing Company, Third Consecutive Year ONLINE PR NEWS,
Published by
PR Newswire
11 Jun 12 Medispec Sees Rapid Worldwide Expansion Medispec Ltd.,
Published by
PR Newswire
11 Jun 12 Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE(TM) Trial Amgen
11 Jun 12 Positive Results from First Human Clinical Trials of a First-Generation Artificial Pancreas System is Significant Step Forward for Millions with Type 1 Diabetes Johnson & Johnson
11 Jun 12 Lyxumia® (lixisenatide) in combination with insulin demonstrates significant reductions in HbA1C and improvements in post-prandial glucose in patients with Type 2 diabetes Sanofi,
Published by
Red Health
11 Jun 12 Research and Markets: Testosterone Replacement Therapy (TRT) - Global Strategic Business Report Research and Markets,
Published by
Business Wire
11 Jun 12 Research and Markets: Analysis of the Stem Cell Markets-Unlocking the New Era in Therapeutics Research and Markets,
Published by
Business Wire
11 Jun 12 BioSante Pharmaceuticals Announces New LibiGel® Phase III Efficacy Trials BioSante Pharmaceuticals Inc.,
Published by
Business Wire
11 Jun 12 Data on GI Dynamics’ EndoBarrier® Therapy Presented at the ADA 72nd Scientific Sessions GI Dynamics Inc.,
Published by
Business Wire
11 Jun 12 MindChild Medical, Inc., Announces Results of National Fetal Monitoring Market Survey MindChild Medical Inc.,
Published by
Business Wire
11 Jun 12 InVivo Therapeutics to Present at Sidoti's Semi-Annual New York Micro-Cap Conference InVivo Therapeutics Holdings Corp.,
Published by
Business Wire
11 Jun 12 PHARMATRAINING GETS HANDS ON WITH NEW TABLETING COURSE PharmaTraining Limited
11 Jun 12 Almac and VTU Technology Form Collaboration to Provide Customers with High Yielding, Fast-Track Generation of Site-Specific Modified Products Almac,
Published by
Business Wire
11 Jun 12 Almac and VTU Technology form collaboration to provide customers with high yielding, fast-track generation of site-specific modified products Almac Group
11 Jun 12 AdvaCare and Matrix Uganda Releasing New Paracetamol Brand Para in East African Markets AdvaCare Pharma
11 Jun 12 CDMO HIRES NEW DIRECTOR SCM Pharma,
Published by
ramarketing
10 Jun 12 Swiss Biotech Association to Exhibit at 2012 BIO International Convention, booth 3135, Jun 18 - 21, 2012, in Boston MA, US Swiss Biotech Association,
Published by
Business Wire
09 Jun 12 FYI from Human Genome Sciences: GlaxoSmithKline Announces New Data from Phase 3 Studies of Once-Weekly Albiglutide in Type 2 Diabetes Human Genome Sciences Inc.,
Published by
Business Wire
09 Jun 12 New Data Show Investigational Compound Dapagliflozin Demonstrated Significant Reductions in Blood Sugar Levels When Added to Sitagliptin in Adults with Type 2 Diabetes at 24 Weeks, with Results Maintained Over 48 Weeks Bristol-Myers Squibb Company and AstraZeneca,
Published by
Business Wire
09 Jun 12 BYDUREON™ Improved A1C, Fasting Glucose, Pulse Pressure and Weight Regardless of Baseline Body Weight in Patients with Type 2 Diabetes Amylin Pharmaceuticals Inc.,
Published by
Business Wire
09 Jun 12 SYMLIN® Use Helped Patients with Type 2 or Type 1 Diabetes Achieve More Time in Normal Glucose Range Amylin Pharmaceuticals Inc.,
Published by
Business Wire
09 Jun 12 BYDUREON™ Was Associated with Significant and Sustained Glycemic Control at Four Years Amylin Pharmaceuticals Inc.,
Published by
Business Wire
09 Jun 12 Once-Weekly BYDUREON™ Provided Greater Glucose Control, Weight Loss and Lower Risk of Hypoglycemia Compared to Once- or Twice-Daily Levemir® in Type 2 Diabetes Amylin Pharmaceuticals Inc.,
Published by
Business Wire
09 Jun 12 New analysis presented at ADA shows improvement in albuminuria with linagliptin in patients at high risk of declining renal function Boehringer Ingelheim,
Published by
Business Wire
09 Jun 12 New linagliptin Phase III data demonstrate significant reductions in blood glucose with no additional risk of hypoglycaemia when combined with insulin in patients with type 2 diabetes Boehringer Ingelheim,
Published by
Business Wire
09 Jun 12 New data demonstrate sustained glucose reduction and weight loss up to 90 weeks with investigational SGLT-2 inhibitor, empagliflozin* Boehringer Ingelheim,
Published by
Business Wire
09 Jun 12 BYETTA® Provided Greater Glycemic Durability and Overall Glycemic Control than Amaryl® in Patients with Type 2 Diabetes Amylin Pharmaceuticals Inc.,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.